Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 10, 2018
- Accepted in final form April 10, 2019
- First Published July 12, 2019.
Article Versions
- Previous version (July 12, 2019 - 12:45).
- You are viewing the most recent version of this article.
Author Disclosures
- David-Axel Laplaud, MD, PhD,
- Romain Casey, PhD,
- Laetitia Barbin, PhD,
- Marc Debouverie, MD, PhD,
- Jérôme De Sèze, MD, PhD,
- David Brassat, MD, PhD,
- Sandrine Wiertlewski, MD,
- Bruno Brochet, MD, PhD,
- Jean Pelletier, MD, PhD,
- Patrick Vermersch, MD, PhD,
- Gilles Edan, MD,
- Christine Lebrun-Frenay, MD,
- Pierre Clavelou, MD, PhD,
- Eric Thouvenot, MD, PhD,
- Jean-Philippe Camdessanché, MD, PhD,
- Ayman Tourbah, MD, PhD,
- Bruno Stankoff, MD, PhD,
- Abdullatif Al Khedr, MD,
- Philippe Cabre, MD, PhD,
- Catherine Lubetzki, MD, PhD,
- Caroline Papeix, MD,
- Eric Berger, MD,
- Olivier Heinzlef, MD,
- Thomas Debroucker, MD,
- Thibault Moreau, MD, PhD,
- Olivier Gout, MD,
- Bertrand Bourre, MD,
- Abir Wahab, MD,
- Pierre Labauge, MD, PhD,
- Laurent Magy, MD, PhD,
- Gilles Defer, MD,
- Anne-Marie Guennoc, MD,
- Nicolas Maubeuge, MD,
- Céline Labeyrie, MD,
- Ivania Patry, MD,
- Chantal Nifle, MD,
- Olivier Casez, MD,
- Laure Michel, MD, PhD,
- Fabien Rollot, MSc,
- Emmanuelle Leray, PhD,
- Sandra Vukusic, MD, PhD,
- Yohann Foucher, PhD;
- on behalf of the SFSEP and OFSEP groups
- David-Axel Laplaud, MD, PhD,
(1) Biogen, (2) TEVA Pharma, (3) Novartis (4) Genzyme(5) Roche(6) MSD
NONE
(1) Biogen(2) Novartis(3) Sanofi-Genzyme(4) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis(3) Roche(4) MedDay
NONE
NONE
(1) Fondation ARSEP(2) Fondation ROCHE
NONE
NONE
NONE
NONE
NONE
NONE
- Romain Casey, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laetitia Barbin, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Debouverie, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jérôme De Sèze, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Brassat, MD, PhD,
Chugai pharma
NONE
Biogen, Bayer, Novartis, sanofi, almirall, Merck, teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
FP7 305477-2012-ongoing and PHRC 2008-2012‐00590638: PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sandrine Wiertlewski, MD,
Scientific advisory board for NOVARTIS, GENZYME, BIOGEN,MERCK, Roche, Sanofi,TEVA.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruno Brochet, MD, PhD,
(1)Roche, (2)Merck, (3) Celgene, (4) Novartis
NONE
Roche (speaker honoraria ), Novartis (speaker honoraria), Biogen (speaker honoraria ) Merck(speaker honoraria),
MSinternational (associate editor)
NONE
NONE
NONE
(1) Novartis, (2) Roche, (3) Merck
NONE
NONE
NONE
Bayer Healthcare, Merck, Novartis, Medday, Biogen-Idec, genzyme,Act?lion and Roche.
Agence Nationale de la Recherche (ANR-10-LABX-57; ANR-10- COHO-002).
NONE
ARSEP, LFSEP
NONE
NONE
NONE
NONE
NONE
NONE
- Jean Pelletier, MD, PhD,
(1) BIOGEN IDEC : member of advisory board (2) NOVARTIS : member of advisory board (3) GENZYME : member of advisory board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ARSEP: research grants Novartis: research grants
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Vermersch, MD, PhD,
Serves on scientific advisory boards for (1) Sanofi, (2) Biogen, (3) Merck, (4) Teva, (5) Novartis, (6) Roche, (7) Servier, (8) Celgene
NONE
(1) Biogen, travel and speaker honoraria; (2) Roche, travel and honoraria; (3) Novartis, honoraria; (4) Teva, travel and honoraria; (5) Sanofi-Aventis, honoraria; (6) Almirall, honoraria (6) Merck Serono, travel and honoraria (7) Celgene, travel and honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from (1) Biogen, (2) Novartis, (3) Merck, (4) Sanofi-Genzyme, (5) Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gilles Edan, MD,
Member of the steering committee of BENEFIT for Bayer and member of the safety monitoring board for Celgene
NONE
travel and speaker honorarium from Sanofi (once) ,biogen (once),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
grant for clinical research activities on MRI (Music project) from Biogen, Mercks, Roche, TEVA, Sanofi, Novartis
PHRC : programme de recherche clinique (Health ministry) : financial support for a clinical research on therapeutic strategy in MS (Natalizumab vs mitoxantrone and immunomodulator drug)2009 and a clinical research on spinal cord MRI in 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christine Lebrun-Frenay, MD,
serving on a scientific advisory board from Biogen, Novartis, Merck, Genzyme,Teva, Roche
NONE
Funding for travel or speaker honoraria from Biogen, Merck, Genzyme, Roche
Serving as editorial advisory board member for Revue Neurologique (Paris) Elsevier, Neurology and therapy.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
UT Southwestern, Dallas, TX. Clinical advisor and senior professor.
Franch MS Society (SFSEP) EDMUS (OFSEP Center) Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Clavelou, MD, PhD,
Novartis (non profit entity) Teva Pharma (non profit entity) Bayer (non profit entity) Biogen (non profit entity) Genzyme-Sanofi (non profit entity) Almirall (non profit entity) Roche (non profit entity)
NONE
Non profit entity, fund directly to department of neurology : Novartis, Teva Pharma, Biogen, Merck, Bayer, Genzyme-Sanofi, Actelion, Roche
Editorial Advisory Board : La lettre du neurologue (french, no financial compensation, since ten years)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Thouvenot, MD, PhD,
(1) Biogen Idec (2) Merck Serono (3) Sanofi Genzyme (4) Novartis (5) Roche (6) Actelion
NONE
Received honoraria for invited lectures from Genzyme, Biogen, Novartis, Merck-Serono and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) PHRC national 2012 (NCT01817166)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jean-Philippe Camdessanché, MD, PhD,
NONE
NONE
Akcea, Alnylam, Biogen, CSL-Behring, Genzyme, Laboratoire Fran?ais des Biotechnologies, Merck-Serono, Novartis, Pfizer, Pharmalliance, Teva, Editions Scientifiques L&C, Edimark, Expression Sant?, Natus, Scien, SNF-Floerger. Honoraria.
Associate editor, Revue Neurologique (Paris). No compensation.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ayman Tourbah, MD, PhD,
Board: Ad Scientam, Medday Pharmaceuticals, Novartis, Merck,
NONE
Biogen, Hikma, Novartis, Medday Pharmaceuticals, Teva Pharma
NONE
NONE
NONE
NONE
Medday Pharmaceuticals
Medday Pharmaceuticals
NONE
NONE
Medday Pharmaceuticals, Biogen, Novartis, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bruno Stankoff, MD, PhD,
scientific advisory boards for Roche, Biogen, Novartis, Sanofi
NONE
Lectures for Biogen, Teva, Genzyme, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research grants from Merck Serono, Genzyme and Roche
NONE
Grants from Fondation ARSEP, fondation pour la recherche medicale (FRM),PMSA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Abdullatif Al Khedr, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philippe Cabre, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Catherine Lubetzki, MD, PhD,
VERTEX , BIOGEN, NOVARTIS, GENZYME, ROCHE
NONE
NONE
Associate editor BRAIN past- editorial board member of MSJ and MSJ and related disorders
NONE
NONE
NONE
BIOGEN, ROCHE, GENZYME,VERTEX, REWIND
NONE
scientific collaboration with EMD SERONO
NONE
scientific collaboration with EMD SERONO, past- Scientific collaboration with VERTEXfinancial support from BIOGEN (for a PhD)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My son is working at GUERBET pharma (contrast agents for imaging). Not any link with the study
- Caroline Papeix, MD,
mercknovartisbiogenrochesanofy
NONE
Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Berger, MD,
NONE
NONE
Biogen Idec, for speakingTeva Pharma, for speakingGenzyme, BoardNovartis, Board and speaking
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Heinzlef, MD,
1.Genzyme advisory Board 2. Novartis advisory board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thomas Debroucker, MD,
1. Novartis2. Sanofi-Aventis3. Biogen-Idec
NONE
NONE
Revue Neurologique (Paris)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Thibault Moreau, MD, PhD,
Thibault Moreau reports receiving consulting fees and speaking fees from Biogen Idec, Sanofi Aventis, Genzyme, Teva Pharma, Bayer Schering, Merck Serono, Roche, Almirall and Novartis, Roche
NONE
NONE
I am redacteur en chef of la lettre du neurologue
NONE
NONE
NONE
I has been non permanent consultant for biogen, genzyme, bayer-schering, novartis, teva, roche for board of research and speakers during meeting with the supports of these compagnies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Gout, MD,
(1) Biogen (2) Genzyme (3) Teva (4) Merck Serono (5), Novartis (6) Medday
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bertrand Bourre, MD,
Served on the scientific advisory boards for Biogen, Novartis, Genzyme, Merck-Serono, Roche, Teva
NONE
Invitation to congress from Biogen, Novartis, Genzyme, Merck-Serono, Roche, Teva
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Abir Wahab, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pierre Labauge, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laurent Magy, MD, PhD,
IDMC Octapharma
NONE
Honoraria for speaking engagements and Travel funded by a commercial entity From Alnylam, Biogen, Novartis Pharma, Pfizer, Pharnext SA, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gilles Defer, MD,
I received personal compensation for scientific advisory board from BiogenIdec, Novartis, Sanofi Aventis, Genzyme and Teva pharmaceutical Industries Ltd
NONE
I received funding for travel and/or speaker honoraria from Merck Serono, BiogenIdec, Guerbet, Sanofi-Aventis, Novartis, Genzyme and Teva pharmaceutical Industries Ltd.
Serve as a chief-associated editor of Revue Neurologique (Paris) (2000-2010)
NONE
NONE
NONE
NONE
NONE
My institution received grants supporting research for my department from Merck Serono, BiogenIdec, Sanofi-Aventis et Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne-Marie Guennoc, MD,
Speaker Honorarium and grant travels from Sanofi
NONE
Honorarium from Roche for my participation in boards
Lettre du Neurologue, reporter, 2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolas Maubeuge, MD,
NONE
NONE
(1) Biogen, funding for travel to conference (2) Genzyme, funding for travel to conference (3) Novartis, funding for travel to conference (4) Merck, funding for travel to conference (5) Roche, funding for travel to conference
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Céline Labeyrie, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ivania Patry, MD,
(1) NOVARTIS (2)Roche (3) GENZYME
NONE
(1) GENZYME funding for travel to conference (2) ROCHE funding for speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NOVARTIS (2) BIOGEN
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chantal Nifle, MD,
(1)Board des experts SEP Ile de France Novartis pharma SAS (2)Board des experts SEP Ile de France GENZYME
NONE
transport and inscription congress: (1) Biogen (2) Sanofi-Genzyme (3)Bayer (4)Novartis (5) Teva (6) Merk-Serono
NONE
NONE
NONE
NONE
NONE
(1) GENZYME (topo post ECTRIMS 2018) (2) ROCHE (topo lancement OCREVUS)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Olivier Casez, MD,
(1) Biogen (2) Novartis (3) Genzyme (4) Roche
NONE
(1) Biogen (funding for travel, speaker honoraria) (2) Novartis (funding for travel, speaker honoraria) (3) Genzyme (funding for travel) (4) Roche (funding for travel, speaker honoraria)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laure Michel, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I rreceived honoraria as consultant from Biogen, Roche, Merck Serono, Sanofi genzyme and Novartis
NONE
NONE
NONE
NONE
NONE
LABEX IGO (INSERM)
ARSEP : association de recherche contre la scl?rose en plaques
NONE
NONE
NONE
NONE
NONE
NONE
- Fabien Rollot, MSc,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Emmanuelle Leray, PhD,
Commercial or non-profit entity: consulting fees from Biogen, Merck, Novartis, and Roche.
NONE
Commercial or non-profit entity: lecture fees or travel grants from Biogen, Merck, Novartis, and Roche.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
ARSEP Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Sandra Vukusic, MD, PhD,
Biogen-Idec, Celg?ne, Geneuro, Genzyme, Medday, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
Biogen-Idec, Genzyme, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
NONE
NONE
NONE
Consultancy in board for Biogen-Idec, Celg?ne, Geneuro, Genzyme, Medday, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
NONE
NONE
Biogen-Idec, Genzyme, Medday, Merck-Serono, Novartis Pharma, Roche, Sanofi Aventis, Teva Pharma
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yohann Foucher, PhD;
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of the SFSEP and OFSEP groups
- From INSERM (D.-A.L., L.B.), CIC 0004, Nantes; CRTI-INSERM UMR U1064 (D.-A.L.), Université de Nantes; Service de Neurologie (D.-A.L., S.W., L. Michel), CHU Nantes; Centre des Neurosciences de Lyon (R.C., F.R., S.V.), Observatoire Français de la Sclérose en Plaques, INSERM 1028 and CNRS UMR5292, Lyon; Université Claude Bernard Lyon 1 (R.C., F.R., S.V.), Université de Lyon; Department of Neurology (M.D.), Nancy University Hospital; Université de Lorraine (M.D.), EA 4360 APEMAC, Vandoeuvre-Lès-Nancy; Department of Neurology and Clinical Investigation Center (J.D.S.), CHU de Strasbourg, INSERM 1434; Department of Neurology (D.B.), CHU de Toulouse; Service de Neurologie (B. Brochet), CHU de Bordeaux; Service de Neurologie (J.P.), Hôpital de la Timone, CRMBM, CNRS, APHM, Aix Marseille Univ, Marseille; Univ Lille (P.V.), CHU Lille, LIRIC (Lille Inflammation Research International Center), INSERM UMR995; Service de Neurologie (G.E., L. Michel), CHU de Rennes; CRCSEP Nice (C.L.-F.), Neurologie Pasteur 2, Université Nice Cote d’Azur, Nice; Service de Neurologie (P. Clavelou), CHU de Clermont-Ferrand; Service de Neurologie (E.T.), CHU de Nîmes; Department of Neurology (J.-P.C.), Hôpital Nord, CHU Saint-Étienne; Service de Neurologie et Faculté de Médecine de Reims (A.T.), CHU de Reims, URCA; Service de Neurologie (B.S.), CHU Saint-Antoine; Service de Neurologie (A.A.K.), CHU d’Amiens; Service de Neurologie (P. Cabre), CHU de Fort de France; Service de Neurologie (C. Lubetzki, C.P.), CHU Pitié-Salpêtrière; Service de Neurologie (E.B.), CHU de Besançon; Service de Neurologie (O.H.), CH de Poissy; Service de Neurologie (T.D.), CH de Saint-Denis; Service de Neurologie (T.M.), CHU de Dijon; Service de Neurologie (O.G.), Fondation Rothschild; Service de Neurologie (B. Bourre), CHU de Rouen; Department of Neurology (A.W.), Hôpital Henri Mondor, Créteil; Service de Neurologie (P.L.), CHU de Montpellier; Service de Neurologie (L. Magy), CHU de Limoges; Service de Neurologie (G.D.), CHU de Caen; CRC SEP and Department of Neurology (A.-M.G.), CHU Bretonneau, Tours; Department of Neurology (N.M.), CHU La Milétrie, Poitiers; Department of Neurology (C. Labeyrie), CHU Bicêtre, Le Kremlin Bicêtre; Department of Neurology (I.P.), Hôpital Sud Francilien, Corbeil Essonnes; Department of Neurology (C.N.), CHU Versailles; Department of Neurology (O.C.), CHU de Grenoble; Ecole des Hautes Etudes en Santé Publique (E.L.), Rennes; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation (S.V.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon/Bron; and INSERM (Y.F.), UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.
- Correspondence
Dr. Laplaud david.laplaud{at}univ-nantes.fr
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.